
Dr. Garcia-Manero on the Data Behind the Luspatercept Approval
Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, joins Chadi Nabhan, MD, MBA, FACP, live at the Eleventh Annual Meeting of the Society of Hematologic Oncology to discuss the phase III COMMANDS trial, the recent approval of luspatercept, and other developments in myelodysplastic syndromes (MDS) treatment and research. Dr. Garcia-Manero spoke about the design of the phase III COMMANDS trial, which evaluated luspatercept versus epoetin alfa for the treatment of anemia in patients with lower-risk MDS who required red blood cell (RBC) transfusions but had not…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.